HK1112753A1 - Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy - Google Patents

Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy

Info

Publication number
HK1112753A1
HK1112753A1 HK08107845.4A HK08107845A HK1112753A1 HK 1112753 A1 HK1112753 A1 HK 1112753A1 HK 08107845 A HK08107845 A HK 08107845A HK 1112753 A1 HK1112753 A1 HK 1112753A1
Authority
HK
Hong Kong
Prior art keywords
application
control
promoter active
cancer therapy
strain expressing
Prior art date
Application number
HK08107845.4A
Other languages
English (en)
Inventor
Gilles Marchal
Mohammad Abolhassani
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of HK1112753A1 publication Critical patent/HK1112753A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK08107845.4A 2006-07-25 2008-07-16 Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy HK1112753A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291205A EP1882741B1 (de) 2006-07-25 2006-07-25 Rekombinanter Mycobakteriumstamm, der ein FAP Protein aus Mycobakterium unter der Kontrolle eines Promotors, der unter hypoxischen Konditionen aktiv ist, exprimiert, und dessen Verwendung zur Tumortherapie

Publications (1)

Publication Number Publication Date
HK1112753A1 true HK1112753A1 (en) 2008-09-12

Family

ID=37026080

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08107845.4A HK1112753A1 (en) 2006-07-25 2008-07-16 Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy

Country Status (10)

Country Link
US (2) US20090304637A1 (de)
EP (2) EP1882741B1 (de)
JP (1) JP2009544305A (de)
AT (2) ATE472602T1 (de)
CA (1) CA2658713A1 (de)
DE (2) DE602006015180D1 (de)
DK (1) DK1882741T3 (de)
ES (1) ES2347812T3 (de)
HK (1) HK1112753A1 (de)
WO (1) WO2008012693A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140598A2 (en) * 2006-12-04 2008-11-20 Bacilligen, Inc. Novel immunotherapeutic mycobacteria, pharmaceutic formulations and uses thereof
EP2620159A1 (de) 2012-01-24 2013-07-31 Institut Pasteur Verbesserte Krebsbehandlung durch Immuntherapie mit BCG- oder antigenetisch ähnlichen nicht-pathogenen Mykobakterien
CA2881635A1 (en) * 2012-08-10 2014-02-13 Memorial Sloan-Kettering Cancer Center Predicting bladder cancer responsiveness to bcg
US10494665B2 (en) * 2014-08-20 2019-12-03 Huawei Yang Test kit and method for testing target nucleic acid in sample
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599510B1 (en) * 1993-11-23 2003-07-29 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US5834306A (en) * 1994-12-23 1998-11-10 Sri International Tissue specific hypoxia regulated therapeutic constructs
WO2000047227A2 (en) * 1999-02-09 2000-08-17 Powderject Vaccines, Inc. Mycobacterium tuberculosis, immunization
AU2003242504A1 (en) * 2002-07-13 2004-02-02 Statens Serum Institut Therapeutic tuberculosis vaccines
EP2206514B1 (de) * 2003-10-16 2014-01-08 The Regents of The University of California Rekombinante, intrazelluläre, immunogene Pathogenzusammensetzungen und Verwendungsverfahren
US7736850B2 (en) * 2003-12-02 2010-06-15 Institute Pasteur Strain of SARS-associated coronavirus and applications thereof

Also Published As

Publication number Publication date
DK1882741T3 (da) 2010-10-11
ES2347812T3 (es) 2010-11-04
EP1882741A1 (de) 2008-01-30
DE602007013248D1 (de) 2011-04-28
CA2658713A1 (en) 2008-01-31
US20120156169A1 (en) 2012-06-21
DE602006015180D1 (de) 2010-08-12
EP1882741B1 (de) 2010-06-30
ATE472602T1 (de) 2010-07-15
ATE502110T1 (de) 2011-04-15
US20090304637A1 (en) 2009-12-10
EP2049667B1 (de) 2011-03-16
WO2008012693A2 (en) 2008-01-31
WO2008012693A3 (en) 2008-04-24
EP2049667A2 (de) 2009-04-22
JP2009544305A (ja) 2009-12-17

Similar Documents

Publication Publication Date Title
MX2010006823A (es) Metodos para el tratamiento de la gota.
NZ725347A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HK1112753A1 (en) Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy
MX2020011768A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MY160628A (en) Therapeutic DLL4 Binding Proteins
WO2007146425A3 (en) Compounds and methods for treatment of chemotherapy-induced anemia
MX2011013457A (es) Polipeptidos que enlazan quimioquina novedosos capaces de inhibir el curso de autoinmunidad, inflamacion y cancer.
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
IN2014CN04401A (de)
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
MY159837A (en) Therapeutic dll4 binding proteins
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
WO2009105585A3 (en) Postsynaptically targeted chemodenervation agents and their methods of use
AP3277A (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases
MX365899B (es) Composición farmacéutica que comprende un fragmento de péptido de hmgb1 para usarse en tratamiento de daño a la medula espinal.
UA99452C2 (ru) Способ стимулирования миелинизации и дифференцирования олигодендроцитов путем применения семафорина 6a
WO2009123950A3 (en) Chimera comprising bacterial cytotoxin and methods of using the same
EP2362904A4 (de) Verfahren zur behandlung oder vorbeugung von blasenkrebs unter verwendung des depdc1-polypeptids
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
MX2021012872A (es) Polipeptidos multiespecificos terapeuticos activados mediante intercambio de cadenas polipeptidicas.
WO2008148932A3 (en) Glycosylasparaginase for treatment of cancers or inflammatory diseases
EP2189531A4 (de) Neues dna-fragment, dieses enthaltender rekombinanter vektor, damit transformierte transformante und nutzung davon
IL292239A (en) Polyethylene glycol-converted kynureninase enzymes and their use for cancer treatment
TW201129375A (en) Treatment of acute ischemic stroke or intracranial bleeding with tPa and carbamylated erythropoietin
KR102508346B9 (ko) 신규 톡소포자충 ｇｒａ８ 유래 재조합 펩타이드 및 이를 포함하는 암 예방 또는 치료용 조성물